Main Page
Jump to navigation
Jump to search
OMNIJOURNAL
Peer-review by everyone
COVID-19 Pandemic
- Find More COVID-19 Papers
- Americas Frontline Doctors speak out (VIDEO)
- Gilead: Twenty-one billion reasons to discredit hydroxychloroquine (ORIGINAL ARTICLE)
- Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
- Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
- Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
- COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
- Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
- Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea
- COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Recently Edited
- Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
- Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
- Forty percent of people with coronavirus infections have no symptoms. Might they be the key to ending the pandemic
- Vitamin D deficiency causes a 10 times higher death rate in Covid-19 patients
- Early treatment with hydroxychloroquine: a country-randomized controlled trial
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- An Effective Treatment for Coronavirus (COVID-19)
- Americas Frontline Doctors Peer Review
- Gilead: Twenty-one billion reasons to discredit hydroxychloroquine (ORIGINAL ARTICLE)
- Gilead: Twenty-one billion reasons to discredit hydroxychloroquine peer review
- COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro